CoChat

Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition

Open access
Toledo, Jon B, Weiner, Michael W, Wolk, David A, Da, Xiao, Chen, Kewei, Arnold, Steven E, Jagust, William, Jack, Clifford, Reiman, Eric M, Davatzikos, Christos, Shaw, Leslie M, Trojanowski, John Q, for the Alzheimer’s Disease Neuroimaging Initiative · 2014 · Acta Neuropathologica Communications

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Based on previous studies, a preclinical classification for Alzheimer's disease (AD) has been proposed. However, 1) specificity of the different neuronal injury (NI) biomarkers has not been studied, 2) subjects with subtle cognitive impairment but normal NI biomarkers (SCINIB) have not been included in the analyses and 3) progression to mild cognitive impairment (MCI) or dementia of the AD type (DAT), referred to here as MCI/DAT, varies between studies. Therefore, we analyzed data from 486 cognitively normal (CN) and 327 DAT subjects in the AD Neuroimaging Initiative (ADNI)-1/GO/2 cohorts. RESULTS: In the ADNI-1 cohort (median follow-up of 6 years), 6.3% and 17.0% of the CN subjects developed MCI/DAT after 3 and 5 years follow-up, respectively. NI biomarker cutoffs [structural magnetic resonance imaging (MRI), fluorodeoxyglucose positron emission tomography (FDG-PET) and cerebrospinal fluid (CSF) tau] were established in DAT patients and memory composite scores were calculated in CN subjects in a cross-sectional sample (n = 160). In the complete longitudinally followed CN ADNI cohort (n = 326, median follow-up of 2 years), CSF and MRI values predicted an increased conversion to MCI/DAT. Different NI biomarkers showed important disagreements for classifying subjects as abnormal NI [kappa = (-0.05)-(0.33)] and into AD preclinical groups. SCINIB subjects (5.0%) were more prevalent than AD preclinical stage 3 subjects (3.4%) and showed a trend for increased progression to MCI/DAT. CONCLUSIONS: Different NI biomarkers lead to different classifications of ADNI subjects, while structural MRI and CSF tau measures showed the strongest predictive value for progression to MCI/DAT. The newly defined SCINIB category of ADNI subjects is more prevalent than AD preclinical stage individuals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/2051-5960-2-26

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Selection of the cohort and clinical outcomes during follow-up.
Figure 1 Selection of the cohort and clinical outcomes during follow-up.CC BY · PubMed Central
Figure 2 Validation of aHV transformation, cognitive and biomarker cutoffs and progression of ADNI-1 CN subjects. Comparisons of cross-validated 1.5-T and corresponding 3-T (a). Progression from CN to MCI/DAT in the ADNI-1 cohort (b). Prevalence of the different CN categories with the use of different neuronal injury biomarkers (c). Conversion of CN subjects to MCI/DAT in adjusted in ADNI-1/GO/2 CN subjects using aHV (d) (dotted line represents cutpoint of the heaviside function), SPARE-AD (e), t-tau/Aβ1–42 ratio (f) and the CN categories defined by the combined NI biomarkers (g).
Figure 2 Validation of aHV transformation, cognitive and biomarker cutoffs and progression of ADNI-1 CN subjects. Comparisons of cross-validated 1.5-T and corresponding 3-T (a). Progression from CN to MCI/DAT in the ADNI-1 cohort (b). Prevalence of the different CN categories with the use of different neuronal injury biomarkers (c). Conversion of CN subjects to MCI/DAT in adjusted in ADNI-1/GO/2 CN subjects using aHV (d) (dotted line represents cutpoint of the heaviside function), SPARE-AD (e), t-tau/Aβ1–42 ratio (f) and the CN categories defined by the combined NI biomarkers (g).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 98

Metadata

Authors
Toledo, J. B., Weiner, M. W., Wolk, D. A., Da, X., Chen, K., Arnold, S. E., Jagust, W., Jack, C., Reiman, E. M., Davatzikos, C., Shaw, L. M., Trojanowski, J. Q., & Initiative, F. T. A. D. N.
Affiliations
  • University of Pennsylvania (US)
  • San Francisco VA Medical Center (US)
  • Banner Alzheimer’s Institute (US)
  • University of California, Berkeley (US)
  • Mayo Clinic (US)
Corresponding author
Trojanowski, John Q
Venue
Acta Neuropathologica Communications
Published
2014-03-06
Volume
2
Issue
1
Pages
26-26
ISSN
2051-5960 (ISSN-L)
OpenAlex
W2112010296
Cited by
89
References
41
Citations by year
2026: 1 · 2025: 4 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 4 · 2020: 9 · 2019: 5 · 2018: 11 · 2017: 10 · 2016: 15 · 2015: 13 · 2014: 2
FWCI
10.17
Type
journal article
Language
en
Open access
Locations
  • Acta Neuropathologica Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Defense (U01 AG024904, W81XWH, W81XWH-12-2-, W81XWH-12, W81XWH1220012, AG024904)
  • Foundation for the National Institutes of Health (W81XWH-12-2-0012, U01AG024904, Grant U01 AG024904, AG024904)
  • Alzheimer's Association (U01 AG024904, W81XWH-12-2-0012)
  • Bristol-Myers Squibb (U01 AG024904, AG024904, W81XWH-12-2-0012)
  • Eli Lilly and Company (U01 AG024904, AG024904, W81XWH-12-2-0012)
  • Pfizer (AG024904, W81XWH-12-2-0012, U01 AG024904)
  • Biogen (W81XWH-12-2-0012, U01 AG024904, AG024904)
  • F. Hoffmann-La Roche (W81XWH-12-2-0012, AG024904, U01 AG024904)
  • Medpace (U01 AG024904)
  • Meso Scale Diagnostics (U01 AG024904, AG024904, W81XWH-12-2-0012)
  • Synarc (U01 AG024904)
  • Alzheimer's Disease Neuroimaging Initiative (W81XWH-12-2–0012, U01AG024904, AG024904, W81XWH-12-2-, Department of Defense award number W81XWH-12-2-0012)
  • BioClinica (U01 AG024904, W81XWH-12-2-0012, AG024904)
  • Novartis Pharmaceuticals Corporation (W81XWH-12-2-0012, U01 AG024904, AG024904)
  • Northern California Institute for Research and Education (U01 AG024904, W81XWH-12-2-0012)
  • Eisai (W81XWH-12-2-0012, U01 AG024904, AG024904)
  • Servier (AG024904, W81XWH-12-2-0012, U01 AG024904)
  • IXICO (AG024904, W81XWH-12-2-0012, U01 AG024904)
  • National Institutes of Health (3u01ag024904-10s2, W81XWH, W81XWH-12-2-0012, U01-AG024904, Grant U01 AG024904, AG024904)
  • Genentech (W81XWH-12-2-0012, AG024904, U01 AG024904)
  • University of California, Los Angeles
  • University of California, San Diego
  • Canadian Institutes of Health Research (U01 AG024904, W81XWH-12-2-0012)
  • National Institute on Aging (U01-AG-024904, W81XWH-12-2–0012, AG 024904, P30AG019610)
  • National Institute of Biomedical Imaging and Bioengineering (W81XWH-12-2-0012, U01 AG024904, P41EB015922, AG024904)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords
Alzheimer's disease, preclinical Alzheimer's disease, Alzheimer's dementia, cerebrospinal fluid tau, structural MRI, FDG-PET, biomarker cut-off values, ADNI cohort
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition, Cross-Sectional Studies, Female, Humans, Male, Neuropsychological Tests, Peptide Fragments, Psychiatric Status Rating Scales, Radionuclide Imaging, Time Factors, Cohort Studies, Biomarkers, Databases, Factual, Amyloid beta-Peptides, tau Proteins, Disease Progression, Fluorodeoxyglucose F18, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. https://app.cochat.ai/papers/10.1186/2051-5960-2-26
The paper
Toledo, J. B., Weiner, M. W., Wolk, D. A., Da, X., Chen, K., Arnold, S. E., Jagust, W., Jack, C., Reiman, E. M., Davatzikos, C., Shaw, L. M., Trojanowski, J. Q., & Initiative, F. T. A. D. N. (2014). Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathologica Communications. https://doi.org/10.1186/2051-5960-2-26

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.